Article Details
Retrieved on: 2024-01-26 17:35:53
Tags for this article:
Click the tags to see associated articles and topics
Summary
Aurum Biosciences secured funding to advance their ABL-101 technology for stroke and spinal cord injury treatment, aligning with 'Public Health' interests by enhancing diagnostic and therapeutic options, endorsed by MHRA and investors.
Article found on: www.digit.fyi
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here